Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cardiogenetic screening amongst families of sudden cardiac death victims: Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors' reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Temporal changes in the incidence of infective endocarditis in Denmark 1997-2017: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 2020 ESC Guidelines for the management of adult congenital heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Work exposure and associated risk of hospitalisation with pneumonia and influenza: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: Oral anticoagulation (OAC) therapy as secondary stroke prophylaxis in atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unexplored and poses a clinical treatment dilemma. We assessed the long-term risk of thromboembolic events according to post-stroke OAC therapy in AF patients with CKD after their first ischaemic stroke.

METHODS AND RESULTS: We identified Danish AF patients with CKD who presented with first-time ischaemic stroke from 2005 to 2014. Chronic kidney disease was defined as a diagnosis code for CKD before baseline, defined as 100 days after stroke discharge. Post-stroke antithrombotic therapy (OAC therapy and antiplatelet therapy) was identified from prescription claims from discharge to baseline. Cumulative incidences and adjusted hazard ratios (HRs) of thromboembolic events according to post-stroke OAC therapy were examined. Of 1252 AF patients with CKD presenting with ischaemic stroke, 631 (50.4%) patients were on OAC therapy and 621 (49.6%) were on antiplatelet therapy alone at baseline [median age 76 (interquartile range, IQR 71-83) and 80 (IQR 72-86), respectively]. The median follow-up period was 1.9 years (IQR 0.8-3.6). Cumulative incidence rates of thromboembolic events and bleeding showed no significant difference between those on OAC therapy and antiplatelet therapy. The results from the multivariable analysis revealed similar results: thromboembolic risk was not modified by OAC treatment [adjusted HR 0.89, 95% confidence interval (CI) 0.73-1.09] nor was the risk of bleeding (adjusted HR 0.88, 95% CI 0.67-1.17).

CONCLUSION: Oral anticoagulation in patients with CKD and prior stroke was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy.

Original languageEnglish
JournalEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Volume22
Issue number5
Pages (from-to)716-723
Number of pages8
ISSN1099-5129
DOIs
Publication statusPublished - 1 May 2020

    Research areas

  • Chronic kidney disease, Ischaemic stroke, Oral anticoagulation therapy, Secondary prevention, Stroke prevention

ID: 58719291